July 29, 2014 by Arezu Sarvestani
A recent spate of mega-mergers hasn’t inspired medtech peers to follow suit just yet, according to leadership at Boston Scientific, C.R. Bard and Smith & Nephew.
The medical device industry has some blockbuster merger activity in recent months, but a few companies are sitting this one out.
Leadership at Boston Scientific (NYSE:BSX), C.R. Bard (NYSE:BCR) and Smith & Nephew (FTSE:SN, NYSE:SNN) all said in recently analyst calls that they aren’t looking to forge mega-mergers of their own, but are instead eying smaller tuck-in buys to complement their existing structures.
